LLY

755.74

-0.21%↓

JNJ

152.57

+0.85%↑

UNH

315.59

+8.36%↑

ABBV

185.7

+0.95%↑

NVO

66.94

+4.04%↑

LLY

755.74

-0.21%↓

JNJ

152.57

+0.85%↑

UNH

315.59

+8.36%↑

ABBV

185.7

+0.95%↑

NVO

66.94

+4.04%↑

LLY

755.74

-0.21%↓

JNJ

152.57

+0.85%↑

UNH

315.59

+8.36%↑

ABBV

185.7

+0.95%↑

NVO

66.94

+4.04%↑

LLY

755.74

-0.21%↓

JNJ

152.57

+0.85%↑

UNH

315.59

+8.36%↑

ABBV

185.7

+0.95%↑

NVO

66.94

+4.04%↑

LLY

755.74

-0.21%↓

JNJ

152.57

+0.85%↑

UNH

315.59

+8.36%↑

ABBV

185.7

+0.95%↑

NVO

66.94

+4.04%↑

Search

Celldex Therapeutics Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

20.41 0.05

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

19.85

Max

20.88

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-5M

-47M

Pardavimai

-480K

695K

Pelnas, tenkantis vienai akcijai

-0.81

Pelno marža

-4,007.83

Darbuotojai

186

EBITDA

-3.9M

-55M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+192.32% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-08-06

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-7.3M

1.3B

Ankstesnė atidarymo kaina

20.36

Ankstesnė uždarymo kaina

20.41

Naujienos nuotaikos

By Acuity

50%

50%

160 / 382 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

Celldex Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-05-18 23:47; UTC

Rinkos pokalbiai

Nikkei May Trade Rangebound Amid Uncertainty Over U.S. Tariffs -- Market Talk

2025-05-18 23:40; UTC

Rinkos pokalbiai

Gold Rises Amid Concerns Over U.S. Fiscal Deficit -- Market Talk

2025-05-18 18:00; UTC

Uždarbis

Tax Bill News; Target, Home Depot, and Snowflake Earnings; and More Stock Market News to Watch This Week -- Barrons.com

2025-05-18 17:01; UTC

Svarbiausios naujienos

GM Is Fighting California on EVs. This Is What It Wants to Overturn and Why. -- Barrons.com

2025-05-18 16:20; UTC

Uždarbis

Tesla Demand Hasn't Rebounded Yet. Watch China This Week. -- Barrons.com

2025-05-18 12:09; UTC

Svarbiausios naujienos

Trump Sounds Upbeat on Ukraine Cease-Fire as Russia Unleashes Drone Barrage -- WSJ

2025-05-17 17:15; UTC

Svarbiausios naujienos

Trump Attacks Walmart for Tariff-Related Price Increases -- WSJ

2025-05-17 09:30; UTC

Svarbiausios naujienos
Uždarbis

In a Trade War, Walmart Lacks Some of Amazon's Ammunition -- Heard on the Street -- WSJ

2025-05-17 08:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-05-17 08:20; UTC

Rinkos pokalbiai
Uždarbis

Financial Services Roundup: Market Talk

2025-05-16 23:18; UTC

Svarbiausios naujienos

U.S. Loses Last Triple-A Credit Rating -- 2nd Update

2025-05-16 22:30; UTC

Svarbiausios naujienos

U.S. Loses Last Triple-A Credit Rating -- Update

2025-05-16 21:56; UTC

Rinkos pokalbiai

Fitch Raises Greece's Outlook to Positive From Stable -- Market Talk

2025-05-16 21:56; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-05-16 21:54; UTC

Svarbiausios naujienos

U.S. Loses Last Triple-A Credit Rating -- WSJ

2025-05-16 21:22; UTC

Rinkos pokalbiai

Moody's Says U.S. Fiscal Performance Likely to Deteriorate -- Market Talk

2025-05-16 21:17; UTC

Rinkos pokalbiai

Treasury Yields Rise, Dollar Falls After Moody's Cuts U.S. Credit Rating -- Market Talk

2025-05-16 21:17; UTC

Svarbiausios naujienos

The Score: UnitedHealth, Walmart, Coinbase Global and More Stocks That Moved on the Week's News -- WSJ

2025-05-16 21:05; UTC

Rinkos pokalbiai

Moody's Downgrades U.S. Credit Rating Due to Deficit, Debts -- Market Talk

2025-05-16 20:55; UTC

Įsigijimai, susijungimai, perėmimai

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

2025-05-16 20:50; UTC

Rinkos pokalbiai
Uždarbis

Financial Services Roundup: Market Talk

2025-05-16 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-05-16 20:37; UTC

Svarbiausios naujienos

Trade Progress Sparks Bullish Week for Wall Street -- WSJ

2025-05-16 20:33; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Dick's-Foot Locker Deal Looks Like a Bet on Nike's Turnaround -- Market Talk

2025-05-16 20:30; UTC

Įsigijimai, susijungimai, perėmimai

Galaxy Digital Begins U.S. Trading as Bitcoin Keeps Powering Ahead -- Barrons.com

2025-05-16 20:18; UTC

Svarbiausios naujienos

Major U.S. Stock Indexes Rise; U.S. Running Out of Patience for Trade Deals -- WSJ

2025-05-16 20:16; UTC

Svarbiausios naujienos

Justice Department Wants to Spare Boeing From Guilty Plea Over 737 MAX Charges -- 3rd Update

2025-05-16 20:15; UTC

Uždarbis

Tesla Stock Rises. Even Hedge Fund Sales Can't Keep It Down. -- Barrons.com

2025-05-16 20:11; UTC

Įsigijimai, susijungimai, perėmimai

Henry Schein: William K. Daniel Joins Board

2025-05-16 20:10; UTC

Įsigijimai, susijungimai, perėmimai

Henry Schein: Strategic Investment by KKR Completed

Akcijų palyginimas

Kainos pokytis

Celldex Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

192.32% į viršų

12 mėnesių prognozė

Vidutinis 59.78 USD  192.32%

Aukščiausias 80 USD

Žemiausias 36 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Celldex Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

10 ratings

9

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

18.91 / 20.63Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bullish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

160 / 382 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.